Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Pulmonary Embolism III: Nursing Management

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026

Same author

Distinct Predictors of Post-thrombotic Symptoms, Signs, and Ulcers after a First Episode Deep Vein Thrombosis: A RIETE Registry Study.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2026

Same author

Reassessing venous thromboembolism risk in the hospital-at-home era: Toward tailored, context-specific assessment.

European journal of internal medicine·2026

Same author

Postthrombotic syndrome: risk after deep vein thrombosis and estimates of its incidence and prevalence in Europe.

Journal of thrombosis and haemostasis : JTH·2026

Same author

The incidence of early recurrent venous thromboembolism: a systematic review and meta-analysis.

Research and practice in thrombosis and haemostasis·2026

Same author

Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE.

Research and practice in thrombosis and haemostasis·2025

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Bemiparin in oncology.

Manuel Monreal Bosch¹, Alfonso Vignoli, Ramón Lecumberri Villamediana

¹Internal Medicine Department, German Trias y Pujol Hospital, Badalona, Barcelona, Spain.

|December 18, 2010

Summary

This summary is machine-generated.

Extended use of low molecular weight heparins (LMWH) after major cancer surgery can prevent dangerous blood clots (VTE). LMWH may also directly inhibit cancer growth and improve patient survival.

More Related Videos

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jun 5, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Area of Science:

Oncology
Hematology
Pharmacology

Background:

The association between cancer and thrombosis (blood clots) is bidirectional, increasing venous thromboembolism (VTE) risk in cancer patients.
A significant portion of VTE events in surgical cancer patients occur post-discharge, indicating a need for extended thromboprophylaxis.
Current guidelines recommend extended prophylaxis but lack strong evidence and are not widely implemented.

Purpose of the Study:

To evaluate the efficacy of extended thromboprophylaxis with bemiparin in preventing VTE after major cancer surgery.
To explore the direct antineoplastic effects of low molecular weight heparins (LMWH) in cancer patients.
To assess the impact of bemiparin on survival in patients with limited small cell lung cancer.

Main Methods:

The Cancer, Bemiparin and Surgery Evaluation (CASE) study investigated extended bemiparin prophylaxis post-surgery.
In-vitro studies examined the anti-angiogenic properties of bemiparin and its derivative RO-14.
Clinical studies investigated the addition of LMWH to chemotherapy regimens.
The Adjuvant Bemiparin in Small Cell Lung Cancer study is assessing bemiparin's effect on survival.

Main Results:

Extended bemiparin prophylaxis significantly reduced major VTE incidence in the CASE study.
LMWH, including bemiparin, demonstrated in-vitro inhibition of angiogenesis, tumor cell invasion, and metastasis.
Clinical studies showed significant survival advantages when LMWH was added to chemotherapy, particularly in limited small cell lung cancer.

Conclusions:

Extended thromboprophylaxis with LMWH, such as bemiparin, is supported by evidence for cancer patients undergoing major surgery.
LMWH possesses direct anti-cancer properties, contributing to improved survival beyond VTE prevention.
Further research, like the ongoing Adjuvant Bemiparin in Small Cell Lung Cancer study, is crucial to confirm survival benefits.